Compare · BIIB vs IMVT
BIIB vs IMVT
Side-by-side comparison of Biogen Inc. (BIIB) and Immunovant Inc. (IMVT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BIIB and IMVT operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- BIIB is the larger of the two at $30.41B, about 3.7x IMVT ($8.27B).
- BIIB has been more active in the news (16 items in the past 4 weeks vs 12 for IMVT).
- Both have 25 recent analyst ratings on file.
- Company
- Biogen Inc.
- Immunovant Inc.
- Price
- -
- -
- Market cap
- $30.41B
- $8.27B
- 1M return
- -
- +19.70%
- 1Y return
- -
- +124.76%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2019
- News (4w)
- 16
- 12
- Recent ratings
- 25
- 25
Biogen Inc.
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB111 and BIIB112 to treat ophthalmology related diseases; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and TMS-007 to treat acute neurology; BIIB074 and BIIB095 for neuropathic pain; and SB11 and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Bristol-Myers Squibb Company; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Ginkgo Bioworks; Capsigen Inc.; and Mirimus, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Immunovant Inc.
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1401, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as has completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
Latest BIIB
- Synapticure Launches Groundbreaking Ataxia Care Program, Expanding Access to Specialized Neurology Nationwide
- Biogen Appoints Michael J. Parini as Chief Legal Officer
- LEQEMBI® Real-World LEADER Study Presented at AAIC® 2026 Finds Over 75% of Early Alzheimer’s Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of Treatment
- LEQEMBI® Real-World LEADER Study Presented at AAIC® 2026 Finds Over 75% of Early Alzheimer's Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of Treatment
- Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer’s Disease
- FDA Approves LEQEMBI IQLIK® (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer’s Disease
- FDA Approves LEQEMBI IQLIK® (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer's Disease
- Biogen upgraded by Truist with a new price target
- Stoke Therapeutics Appoints Thomas McCauley, Ph.D., as Chief Scientific Officer
- LEQEMBI® Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer’s Disease Presented at the Alzheimer’s Association International Conference® (AAIC®) 2026
Latest IMVT
- Chief Operating Officer Gloria Melanie sold $80,532 worth of shares (2,036 units at $39.55), decreasing direct ownership by 0.91% to 222,357 units (SEC Form 4) to satisfy withholding tax
- Chief Legal Officer Van Tuyl Christopher sold $47,702 worth of shares (1,206 units at $39.55), decreasing direct ownership by 0.67% to 179,391 units (SEC Form 4) to satisfy withholding tax
- Chief Technology Officer Stout Jay S sold $137,925 worth of shares (3,487 units at $39.55), decreasing direct ownership by 2% to 208,198 units (SEC Form 4) (tax withholding)
- Chief Executive Officer Venker Eric sold $118,980 worth of shares (3,092 units at $38.48), exercised 92,188 shares at a strike of $14.46 and returned $3,304,030 worth of shares to the company (86,629 units at $38.14), increasing direct ownership by 0.98% to 254,280 units (SEC Form 4) (withholding obligation)
- Chief Operating Officer Gloria Melanie sold $678,604 worth of shares (17,714 units at $38.31), decreasing direct ownership by 7% to 224,393 units (SEC Form 4)
- Chief Technology Officer Stout Jay S sold $1,532,309 worth of shares (40,000 units at $38.31), decreasing direct ownership by 16% to 211,685 units (SEC Form 4)
- Chief Legal Officer Van Tuyl Christopher exercised 17,824 shares at a strike of $15.20 and sold $682,887 worth of shares (17,824 units at $38.31) (SEC Form 4)
- Chief Financial Officer Girao Tiago exercised 10,000 shares at a strike of $15.90 and sold $384,600 worth of shares (10,000 units at $38.46) (SEC Form 4)
- Director Pande Atul exercised 1,500 shares at a strike of $8.43 and sold $57,015 worth of shares (1,500 units at $38.01) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 144 filed by Immunovant Inc.